Drug Trial Radar · NCT04203056
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
Last checked: Nov 20, 2026Latest source record: Nov 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
15
Actual
Start
Dec 16, 2019
Primary completion
Oct 1, 2022
Study completion Oct 1, 2022
Sponsor
- Lead sponsor
- University of California, Los AngelesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alkermes, Inc.
- First posted
- Dec 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
Conditions
- Schizophrenia
- Schizoaffective Disorder, Depressive Type
- Schizophreniform Disorder
Interventions
Aripiprazole LauroxilDrug
12 month longitudinal aripiprazole lauroxil treatment and assessment follow-through
ARI-ORALDrug
oral aripiprazole
AL-NCDDrug
Aripiprazole Lauroxil 675 MG/2.4 ML Intramuscular Suspension, Extended Release
Primary outcomes
What the sponsor says the trial is designed to measure.
- Exacerbation or Relapse of Psychotic SymptomsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California, Los Angeles
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.